In vitro characterization of the angiogenic phenotype and genotype of the endothelia derived from sporadic cerebral cavernous malformations

Neurosurgery

Volumn 69, Issue 3, 2011, Pages 722-731

  Zhu, Yuan ^a   Wu, Qun ^a,b   Fass, Moritz ^c   Xu, Jin Fang ^a,b   You, Chao ^a   Müller, Oliver ^a   Sandalcioglu, I Erol ^a   Zhang, Jian Min ^b   Sure, Ulrich ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Angiogenesis; CCM1 gene siRNA; Cerebral cavernous malformations; Endothelium; VEGF and receptors

Indexed keywords

CCM1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ANGIOGENESIS; APOPTOSIS; ARTICLE; CAVERNOUS HEMANGIOMA; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FETAL CALF SERUM; GENE EXPRESSION; GENE SILENCING; GENOTYPE; HUMAN; HUMAN CELL; HYPOXIA; MALE; MICROVASCULAR ENDOTHELIAL CELL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STIMULUS RESPONSE;

ADULT; APOPTOSIS; CELL HYPOXIA; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; CELL SEPARATION; DNA, COMPLEMENTARY; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE SILENCING; GENOTYPE; HEMANGIOMA, CAVERNOUS, CENTRAL NERVOUS SYSTEM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MALE; NEOVASCULARIZATION, PATHOLOGIC; ORGAN CULTURE TECHNIQUES; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 80051789017     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e318219569f     Document Type: Article

References (29)

1. Awad IA. Unfolding knowledge on cerebral cavernous malformations. Surg Neurol. 2005;63(4):317-318.
2. Riant F, Bergametti F, Ayrignac X, Boulday G, Tournier-Lasserve E. Recent insights into cerebral cavernous malformations: The molecular genetics of CCM. FEBS J. 2010;277(5):1070-1075.
3. Petit N, Blecon A, Denier C, Tournier-Lasserve E. Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr Patterns. 2006;6(5):495-503.
4. Seker A, Pricola KL, Guclu B, Ozturk AK, Louvi A, Gunel M. CCM2 expression parallels that of CCM1. Stroke. 2006;37(2):518-523.
5. Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: Complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet. 2009;18(5):911-918.
6. Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): Evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet. 2009;18(5):919-930.
7. Boulday G, Blecon A, PetitN, et al. Tissue-specific conditional CCM2 knockoutmice establish the essential role of endothelial CCM2 in angiogenesis: Implications for human cerebral cavernous malformations. Dis Model Mech. 2009;2(3-4):168-177.
8. Whitehead KJ, Plummer NW, Adams JA, Marchuk DA, Li DY. Ccm1 is required for arterial morphogenesis: Implications for the etiology of human cavernous malformations. Development. 2004;131(6):1437-1448.
9. Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA. Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am J Pathol. 2004;165(5): 1509-1518.
10. Plummer NW, Squire TL, Srinivasan S, et al. Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm Genome. 2006;17(2):119-128.
11. Kleaveland B, Zheng X, Liu JJ, et al. Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway. Nat Med. 2009;15(2):169-176.
12. Gault J, Awad IA, Recksiek P, et al. Cerebral cavernous malformations: Somatic mutations in vascular endothelial cells. Neurosurgery. 2009;65(1):138-144; discussion 144-135.
13. Zhu Y, Peters C, Hallier-Neelsen M, et al. Phosphatase and tensin homolog in cerebral cavernous malformation: A potential role in pathological angiogenesis. J Neurosurg. 2009;110(3):530-539.
14. Zhu Y, Wloch A, Wu Q, et al. Involvement of PTEN promoter methylation in cerebral cavernous malformations. Stroke. 2009;40(3):820-826.
15. Baev NI, Awad IA. Endothelial cell culture from human cerebral cavernous malformations. Stroke. 1998;29(11):2426-2434.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
17. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 1998;143(5):1341-1352.
18. Wuestehube J, Bartol A, Liebler SS, et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A. 2010;107(28):12640-12645.
19. Abe T, Morishige M, Ooba H, et al. The association between high VEGF levels and multiple probable punctuate cavernous malformations. Acta Neurochir (Wien). 2009;151(7):855-859.
20. Sandalcioglu IE, Wende D, Eggert A, et al. Vascular endothelial growth factor plasma levels are significantly elevated in patients with cerebral arteriovenous malformations. Cerebrovasc Dis. 2006;21(3):154-158.
21. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5 (suppl 1):3-10.
22. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47(3):149-161.
23. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029-1039.
24. Rahimi N. VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy. Front Biosci. 2006;11:818-829.
25. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443(7114):993-997.
26. Faurobert E, Albiges-Rizo C. Recent insights into cerebral cavernous malformations: A complex jigsaw puzzle under construction. FEBS J. 2010;277(5): 1084-1096.
27. Zhu Y, Wu Q, Xu JF, et al. Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations. Neurosurg Focus. 2010;29(3):E1.
28. Borikova AL, Dibble CF, Sciaky N, et al. Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem. 2010;285(16):11760-11764.
29. Zhang J, Basu S, Rigamonti D, Dietz HC, Clatterbuck RE. Krit1 modulates beta 1-integrin-mediated endothelial cell proliferation. Neurosurgery. 2008;63(3):571-578; discussion 578.